Dupuytren's disease: State of knowledge and research in physiopathology;Maladie de Dupuytren: état des connaissances et de la recherche en physiopathologie

Chirurgie de la Main

Volumn 30, Issue 4, 2011, Pages 239-245

  Carvalhana, G ^a   Auquit Auckbur, I ^a   Milliez, P Y ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Cellular junction; Genetical abnormalities; Growth factors; Metalloproteinases; Myofibroblast

Indexed keywords

CATENIN; COLLAGEN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRONECTIN; GROWTH FACTOR; METALLOPROTEINASE; MYC PROTEIN; ONCOPROTEIN; TRANSCRIPTION FACTOR MAF;

CELL JUNCTION; CELL PROLIFERATION; DUPUYTREN CONTRACTURE; GENE OVEREXPRESSION; GENETIC DISORDER; HUMAN; MYOFIBROBLAST; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PROTO ONCOGENE; SHORT SURVEY; ULTRASTRUCTURE;

BIOMEDICAL RESEARCH; DUPUYTREN CONTRACTURE; EXTRACELLULAR MATRIX; HUMANS; INTERCELLULAR JUNCTIONS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS;

EID: 80052961347     PISSN: 12973203     EISSN: 17696666     Source Type: Journal    
DOI: 10.1016/j.main.2011.03.002     Document Type: Short Survey

References (29)

1. Merle M. Affections rhumatismales, dégénératives, syndromes canalaires. Chirurgie de la main 2007, Masson, Paris, p. 245-308. vol. 3.
2. Ullah A.S., Dias J.J., Bhowal B. Does a 'firebreak' full-thickness skin graft prevent recurrence after surgery for Dupuytren's contracture?. J Bone Joint Surg Br 2009, 91(3):374-378.
3. Gudmundsson K.G., Arngrímsson R., Sigfússon N., Jónsson T. Increased mortality and cancer mortality in men with Dupuytren's disease: a 15-year follow up study. J Clin Epidemiol 2002, 55(1):5-10.
4. Tubiana R. Maladie de Dupuytren. Malformations congénitales. Amputations, prothèse, rééducation, la main dans l'Art. Traité de chirurgie de la main 1998, Masson, Paris, p. 8-25. Tome 6.
5. Seyhan H., Kopp J., Schultze-Mosgau S., Horch R.E. Increased metabolic activity of fibroblasts derived from cords compared with nodule fibroblasts sampling from patients with Dupuytren's contracture. Plast Reconstr Surg 2006, 117(4):1248-1252.
6. Jemec B., Linge C., Grobbelaar A.O., Smith P.J., Sanders R., McGrouther D.A. The effect of 5-florouracile on Dupuytren fibroblast proliferation and differentiation. Chir Main 2000, 19(1):15-22.
7. Jemec B., Grobbelaar A.O., Wilson G.D., Smith P.J., Sanders R., McGrouther D.A. Is Dupuytren's disease caused by an imbalance between proliferation and cell death?. J Hand Surg Br 1999, 24(5):511-514.
8. Lee L.C., Lee L.C., Zhang A.Y., Chong A.K., Pham H., Longaker M.T., et al. Expression of a novel gene, MafB, in Dupuytren's disease. J Hand Surg Am 2006, 31(2):211-218.
9. Augoff K., Ratajczak K., Gosk J., Tabola R., Rutowski R. Gelatinase A activity in Dupuytren's disease. J Hand Surg Am 2006, 31(10):1635-1639.
10. Johnston P., Larson D., Clark I.M., Chojnowski A.J. Metalloproteinase gene expression correlates with clinical outcome in Dupuytren's disease. J Hand Surg Am 2008, 33(7):1160-1167.
11. Johnston P., Chojnowski A.J., Davidson R.K., Riley G.P., Donell S.T., Clark I.M. A complete expression profile of Matrix-Degrading Metalloproteinases in Dupuytren's disease. J Hand Surg Am 2007, 32A:343-351.
12. Tomasek F.F., Vaughan M.B., Haaksma C.J. Cellular structure and biology of Dupuytren's disease. Hand Clin 1999, 15(1):21-34.
13. Ulrich D., Ulrich F., Piatkowski A., Pallua N. Expression of matrix metalloproteinases and their inhibitors in cords and nodules of patients with Dupuytren's disease. Arch Orthop Trauma Surg 2009, 129(11):1453-1459.
14. Ulrich D., Hrynyschyn K., Pallua N. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease. Plast Reconstr Surg 2003, 112(5):1279-1286.
15. Shih B., Brown J.J., Armstrong D.J., Lindau T., Bayat A. Differential gene expression analysis of subcutaneous fat, fascia and skin overlying a Dupuytren's disease nodule in comparison to control tissue. Hand 2009, 4(3):294-301.
16. O'Gorman D.B., Wu Y., Seney S., Zhu R.D., Gan B.S. Wnt expression is not correlated with beta-catenin dysregulation in Dupuytren's disease. J Negat Results Biomed 2006, 30:5-13.
17. Howard J.C., Varallo V.M., Ross D.C., Roth J.H., Faber K.J., Alman B.J., et al. Elevated levels of beta-catenin and fibronectin in 3-dimensional collagen cultures of Dupuytren's disease cells are regulated by tension in vitro. BMC Musculoskelet Disord 2003, 16:4-16.
18. Howard J.C., Varallo V.M., Ross D.C., Faber K.J., Roth J.H., Seney S., et al. Wound healing-associated proteins Hsp47 and fibronectin are elevated in Dupuytren's contracture. J Surg Res 2004, 117(2):232-238.
19. Badalamente M.A., Sampson S.P., Hurst L.C., Dowd A., Miyasaka K. The role of transforming growth factor beta in Dupuytren's disease. J Hand Surg Am 1996, 21(2):210-215.
20. Alioto R.J., Rosier R.N., Burton R.I., Puzas J.E. Comparative effects of growth factors on fibroblasts of Dupuytren's tissue and normal palmar fascia. J Hand Surg Am 1994, 19(3):442-452.
21. Bisson M.A., Beckett K.S., McGrouther D.A., Grobbelaar A.O., Mudera V. Transforming growth factor beta 1 stimulation enhances Dupuytren's fibroblast contraction in response to uniaxial mechanical load within a 3-dimensional collagen gel. J Hand Surg Am 2009, 34(6):1102-1110.
22. Tomasek J.J., Vaughan M.B., Haaksma C.J. Cellular structure and biology of Dupuytren's disease. Hand Clin 1999, 15(1):21-34.
23. Bayat A., Watson J.S., Stanley J.K., Ferguson M.W., Ollier W.E. Genetic susceptibility to dupuytren disease: association of Zf9 transcription factor gene. Plast Recontr Surg 2003, 111(7):2133-2139.
24. Kopp J., Seyhan H., Müller B., Lanczak J., Pausch E., Gressner A.M., et al. N-acetyl-L-cysteine abrogates fibrogenic properties of fibroblasts isolated from Dupuytren's disease by blunting TGF-beta signalling. J Cell Mol Med 2006, 10(1):157-165.
25. Tse R., Howard J., Wu Y., Gan B.S. Enhanced Dupuytren's disease fibroblast populated collagen lattice contraction is independent of endogenous active TGF-beta2. BMC Musculoskelet Disord 2004, 5(1):41.
26. Kuhn M.A., Wang X., Payne W.G., Ko F., Robson M.C. Tamoxifen decreases fibroblast function and downregulates TGF-beta2 in Dupuytren's affected palmar fascia. J Surg Res 2002, 103(2):146-152.
27. Augoff K., Kula J., Gosk J., Rutowski R. Epidermal growth factor in Dupuytren's disease. Plast Reconstr Surg 2005, 115(1):128-133.
28. Augoff K., Taboła R., Kula J., Gosk J., Rutowski R. Epidermal growth factor receptor in Dupuytren's disease. J Hand Surg Br 2005, 30(6):570-573.
29. Kraljevic Pavelic S., Sedic M., Hock K., Vucinic S., Jurisic D., Gehrig P., et al. An integrated proteomics approach for studying the molecular pathogenesis of Dupuytren's disease. J Pathol 2009, 217(4):524-533.